| 2024-07-29 | +34.6% | M&A | Seeking Alpha | Cipher Pharmaceuticals acquires dermatology products from ParaPRO |
| 2025-03-18 | +19.4% | earnings | Seeking Alpha | Cipher Pharmaceuticals GAAP EPS of $0.13 misses by $0.02, revenue of $11.82M misses by $0.43M |
| 2024-03-15 | +18.6% | earnings | Seeking Alpha | Cipher Pharmaceuticals Inc. (CPHRF) Q4 2023 Earnings Call Transcript |
| 2024-11-08 | -17.9% | earnings | Seeking Alpha | Cipher Pharmaceuticals Inc. (CPHRF) Q3 2024 Earnings Call Transcript |
| 2024-11-08 | -17.9% | earnings | Seeking Alpha | Cipher Pharmaceuticals reports Q3 results |
| 2023-11-10 | +16.5% | earnings | Seeking Alpha | Cipher Pharmaceuticals Inc. (CPHRF) Q3 2023 Earnings Call Transcript |
| 2026-03-12 | +15.8% | earnings | CNW Group | Cipher Pharmaceuticals Reports Fourth Quarter Results and Full Year 2025 Record Revenue and Earnings |
| 2026-03-12 | +15.8% | news | Seeking Alpha | Cipher Pharmaceuticals reports FY results |
| 2026-03-12 | +15.8% | earnings | Yahoo! Finance Canada | Cipher Pharmaceuticals Reports Fourth Quarter Results and Full Year 2025 Record Revenue and Earnings - Yahoo! Finance Canada |
| 2024-03-14 | +14.0% | earnings | Seeking Alpha | Cipher Pharmaceuticals GAAP EPS of $0.32, revenue of $4.9M |
| 2026-03-13 | +14.0% | earnings | GuruFocus.com | Cipher Pharmaceuticals Inc (CPHRF) Q4 2025 Earnings Call Highlights: Revenue and Earnings Surge ... |
| 2026-03-13 | +14.0% | earnings | Seeking Alpha | Cipher Pharmaceuticals Inc. (CPH:CA) Q4 2025 Earnings Call Transcript |
| 2025-05-09 | -12.7% | earnings | Seeking Alpha | Cipher Pharmaceuticals Inc. (CPHRF) Q1 2025 Earnings Call Transcript |
| 2025-05-09 | -12.7% | earnings | Seeking Alpha | Cipher Pharmaceuticals GAAP EPS of $0.10, revenue of $12M |
| 2025-03-19 | +10.7% | earnings | Seeking Alpha | Cipher Pharmaceuticals GAAP EPS of $0.13, revenue of $11.82M misses by $0.28M |
| 2025-03-19 | +10.7% | earnings | Seeking Alpha | Cipher Pharmaceuticals Inc. 2024 Q4 - Results - Earnings Call Presentation |
| 2025-03-19 | +10.7% | earnings | Seeking Alpha | Cipher Pharmaceuticals Inc. (CPHRF) Q4 2024 Earnings Call Transcript |
| 2025-08-08 | +10.4% | earnings | Seeking Alpha | Cipher Pharmaceuticals Inc. (CPHRF) Q2 2025 Earnings Call Transcript |
| 2025-08-08 | +10.4% | earnings | Seeking Alpha | Cipher Pharmaceuticals reports Q2 results |
| 2025-11-07 | -9.5% | earnings | Seeking Alpha | Cipher Pharmaceuticals Inc. (CPH:CA) Q3 2025 Earnings Call Transcript |
| 2023-11-09 | +9.2% | earnings | Seeking Alpha | Cipher Pharmaceuticals GAAP EPS of $0.27, revenue of $6.1M |
| 2025-11-06 | -7.9% | earnings | Seeking Alpha | Cipher Pharmaceuticals GAAP EPS of $0.21 beats by $0.08, revenue of $12.83M misses by $0.53M |
| 2023-05-12 | +7.7% | earnings | Seeking Alpha | Cipher Pharmaceuticals Inc. (CPHRF) Q1 2023 Earnings Call Transcript |
| 2023-03-17 | -6.7% | earnings | Seeking Alpha | Cipher Pharmaceuticals Inc. (CPHRF) Q4 2022 Earnings Call Transcript |
| 2023-05-11 | +6.6% | earnings | Seeking Alpha | Cipher Pharmaceuticals GAAP EPS of $0.10 beats by $0.02, revenue of $4.9M misses by $0.64M |
| 2023-03-16 | -4.6% | earnings | Seeking Alpha | Cipher Pharmaceuticals Non-GAAP EPS of -$0.12 |
| 2026-04-07 | -3.1% | expansion | Business Wire | CaryHealth Launches Direct-to-Patient Program for Cipher Pharmaceuticals’ Natroba™ (spinosad) |
| 2024-05-10 | -2.9% | earnings | Seeking Alpha | Cipher Pharmaceuticals Inc. (CPHRF) Q1 2024 Earnings Call Transcript |
| 2025-11-23 | -2.9% | news | Seeking Alpha | Cipher Pharmaceuticals Has Potential |
| 2025-11-22 | -2.9% | news | Seeking Alpha | Cipher Pharmaceuticals Has Potential (OTCMKTS:CPHRF) - Seeking Alpha |
| 2025-10-14 | +2.7% | news | Yahoo Finance | Cipher Pharmaceuticals Receives Successful Arbitration Award - Yahoo Finance |
| 2023-08-11 | +2.6% | earnings | Seeking Alpha | Cipher Pharmaceuticals Inc. (CPHRF) Q2 2023 Earnings Call Transcript |
| 2023-08-11 | +2.6% | earnings | Seeking Alpha | Cipher Pharmaceuticals GAAP EPS of $0.12, revenue of $5.3M |
| 2024-08-09 | -1.8% | earnings | Seeking Alpha | Cipher Pharmaceuticals GAAP EPS of $0.12, revenue of $5.3M |
| 2025-10-29 | -1.8% | earnings | Yahoo Finance | Cipher Pharmaceuticals Schedules Q3 2025 Earnings Release and Conference Call - Yahoo Finance |
| 2026-03-14 | -1.8% | earnings | GuruFocus.com | Cipher Pharmaceuticals Inc (CPHRF) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... |
| 2025-10-15 | -1.7% | earnings | Seeking Alpha | Halvio Capital adds Mestek, exits Daktronics in Q3 |
| 2024-05-09 | +1.7% | earnings | Seeking Alpha | Cipher Pharmaceuticals GAAP EPS of $0.20 beats by $0.10, revenue of $5.9M beats by $0.87M |
| 2025-07-23 | -0.9% | earnings | Investing.com | Cipher Pharmaceuticals Q1 2025 slides: Natroba acquisition drives revenue growth despite EPS miss - Investing.com |
| 2026-03-16 | -0.8% | analyst | MT Newswires | Stifel Canada Lifts Cipher Pharmaceuticals Price Target By $1 |
| 2026-01-28 | -0.7% | earnings | CNW Group | Cipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba™ (Spinosad) |
| 2026-03-04 | -0.3% | earnings | CNW Group | Cipher Pharmaceuticals Schedules Q4 & Fiscal 2025 Earnings Release and Conference Call |
| 2026-03-04 | -0.3% | earnings | Yahoo Finance | Cipher Pharmaceuticals Schedules Q4 & Fiscal 2025 Earnings Release and Conference Call - Yahoo Finance |
| 2025-07-25 | +0.2% | news | Finimize | Cipher Pharma’s Bet On Dermatology Delivers Standout Growth - Finimize |
| 2026-04-24 | — | news | Simply Wall St. | Unveiling Three Undiscovered Gems in Canada |